Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Biomaterials. 2023 May 31;300:122185. doi: 10.1016/j.biomaterials.2023.122185

Figure 5. Intratumoral injection of tAPC reprogramming NPs elicits a strong and long-term anti-tumor effect.

Figure 5.

(A) Schematic of NP and anti-PD-1 (aPD1) dosing regimen. Tumor area measurements for (B) E0771 and (D) E0771 survivors rechallenge. Kaplan-Meier survival plots for (D) E0771 and (E) E0771 survivors rechallenge. For A, statistically significant differences in the growth rate were measured by two-way ANOVA with Dunnett’s post-test. For B and E, differences in survival were calculated by the Mantel-Cox log-rank test compared to controls Group 1 (fLuc NPs) and naïve, respectively, with Bonferroni p-value correction for multiple comparisons. All graphs show mean ± SE. Seven or eight (n=7-8) mice were used per group. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001